Global understanding of complement has shifted and developed since the 21st century: from our idea of a blood-based antibiotic system to a global regulator of immunity and tissue homeostasis. Recent ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...

Atypical haemolytic uremic syndrome (aHUS) is an uncommon, yet potentially life‐threatening disorder predominantly characterised by dysregulation of the alternative complement pathway. Unlike the more ...

– ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) – “ULTOMIRIS has already provided patients with greater flexibility ...

Complement inhibitors continue to serve as the cornerstone of aHUS management, with high satisfaction reported for Alexion’s Soliris and Ultomiris. Hematologists report broader prescribing experience, ...

Understanding the ins and outs of a rare disease like atypical hemolytic uremic syndrome (aHUS) is a difficult task for anyone, but it can be especially confusing for young children, in whom the rare ...

The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...